Parabilis Medicines: Funding, Investors & Team (Sep 2026)
Parabilis Medicines is a biopharmaceutical company in the clinical stage that focuses on developing exceptional medications targeting challenging protein structures previously deemed undruggable. Utilizing more than ten years of exclusive data, innovative laboratory techniques, and algorithms based on AI and physics, the company has introduced a novel category of stabilized, cell-penetrating alpha-helical peptides known as Helicons™. These peptides can modulate intracellular proteins that traditional drug modalities cannot reach.
Parabilis Medicines has raised $380M across 2 funding rounds on record, the most recent an undisclosed round of $75.0M announced in Jun 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Parabilis Medicines Company Profile and Key Stats
Latest funding round on record: Jun 2026.
Parabilis Medicines Funding Rounds
Parabilis Medicines raised $305M in a Series F announced in Jan 2026.
5 months later, an undisclosed round of $75.0M was announced in Jun 2026.
Parabilis Medicines Founders and Leadership Team
No contact details are on record for this team yet.
Parabilis Medicines Funding Compared to Other Biotechnology Startups
Parabilis Medicines' latest round of $75.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Parabilis Medicines in Biotechnology and Cambridge
Companies Similar to Parabilis Medicines
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Parabilis Medicines Funding FAQs
What does Parabilis Medicines do?
Parabilis Medicines is a biopharmaceutical company in the clinical stage that focuses on developing exceptional medications targeting challenging protein structures previously deemed undruggable. Utilizing more than ten years of exclusive data, innovative laboratory techniques, and algorithms based on AI and physics, the company has introduced a novel category of stabilized, cell-penetrating alpha-helical peptides known as Helicons™. These peptides can modulate intracellular proteins that traditional drug modalities cannot reach.
How much funding has Parabilis Medicines raised?
Parabilis Medicines has raised $380M across 2 rounds on record. The most recent is an undisclosed round of $75.0M announced in Jun 2026.
When did Parabilis Medicines last raise funding?
Parabilis Medicines' most recent funding round on record is an undisclosed round of $75.0M, announced in Jun 2026.
Who founded Parabilis Medicines?
FundedIQ lists Mathai Mammen (Founder), Weiqing Zhou (Founder) at Parabilis Medicines.
Where is Parabilis Medicines headquartered?
Parabilis Medicines is based in Cambridge, Massachusetts, United States.
How many employees does Parabilis Medicines have?
Parabilis Medicines is in the 101-250 employee band.
How does Parabilis Medicines' funding compare to other Biotechnology startups?
Parabilis Medicines' latest round of $75.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Parabilis Medicines Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Parabilis Medicines is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.